{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:20Z","timestamp":1790463260005,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11899-020-00589-y","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T15:04:05Z","timestamp":1589209445000},"page":"372-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["PD-1\/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas"],"prefix":"10.1007","volume":"15","author":[{"given":"Wei","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467\u201377.","journal-title":"Nat Rev Immunol"},{"key":"589_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348.","journal-title":"Annu Rev Immunol"},{"key":"589_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","volume":"25","author":"KM Zak","year":"2017","unstructured":"Zak KM, Grudnik P, Magiera K, D\u00f6mling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2. Structure. 2017;25:1163\u201374.","journal-title":"Structure"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131:68\u201383.","journal-title":"Blood"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","volume":"30","author":"Y Xia","year":"2016","unstructured":"Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 2016;30:189\u2013200.","journal-title":"Blood Rev"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261\u20138.","journal-title":"Nat Immunol"},{"key":"589_CR9","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384\u201391.","journal-title":"J Clin Invest"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","volume":"111","author":"T Azuma","year":"2008","unstructured":"Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111:3635\u201343.","journal-title":"Blood"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14712598.2019.1659777","volume":"19","author":"S Sheikh","year":"2019","unstructured":"Sheikh S, Kuruvilla J. Pembrolizumab for the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2019;19:1119\u201326.","journal-title":"Expert Opin Biol Ther"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846\u201356.","journal-title":"Cancer Immunol Res"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"589_CR17","doi-asserted-by":"crossref","unstructured":"Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules. 2019;24.","DOI":"10.3390\/molecules24061190"},{"key":"589_CR18","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Revised Fourth Edition ed","author":"SHCE Swerdlow","year":"2017","unstructured":"Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised Fourth Edition ed. 2017."},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220\u20134.","journal-title":"Blood"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","volume":"122","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122:2856\u201363.","journal-title":"Blood"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","volume":"40","author":"S Muenst","year":"2009","unstructured":"Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009;40:1715\u201322.","journal-title":"Hum Pathol"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12788","volume":"152","author":"T Jelinek","year":"2017","unstructured":"Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152:357\u201371.","journal-title":"Immunology"},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","volume":"54","author":"T Menter","year":"2016","unstructured":"Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17\u201324.","journal-title":"Hum Pathol"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690\u20137.","journal-title":"J Clin Oncol"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"\u2022\u2022 Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139 In this phase 1 study, nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin\u2019s lymphoma.","journal-title":"N Engl J Med"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"\u2022 Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462\u201373 This study identifed a group of lymphomas that should be considered for PD-1\/PD-L1-directed therapies, and validate methods to detect PD-L1 in FFPE tissue biopsies.","journal-title":"Clin Cancer Res"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood"},{"key":"589_CR28","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"\u2022\u2022 Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733\u20139 In this phase 1b study, pembrolizumab treatment induced favorable responses in a heavily pretreated patients with CHL.","journal-title":"J Clin Oncol"},{"key":"589_CR29","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","volume":"127","author":"K Georgiou","year":"2016","unstructured":"\u2022 Georgiou K, Chen L, Berglund M, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127:3026\u201334 This study demonstrated the genetic basis of PD-L1 overexpression in DLBCL and suggest that treatments targeting the PD-1-PD-L1\/PD-L2 axis might benefit DLBCL patients.","journal-title":"Blood"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","volume":"132","author":"L Li","year":"2018","unstructured":"Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, et al. B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018;132:1805\u201317.","journal-title":"Blood"},{"key":"589_CR31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193\u2013201.","journal-title":"Blood"},{"key":"589_CR32","doi-asserted-by":"publisher","first-page":"59976","DOI":"10.18632\/oncotarget.11045","volume":"7","author":"W Xing","year":"2016","unstructured":"Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, et al. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget. 2016;7:59976\u201386.","journal-title":"Oncotarget"},{"key":"589_CR33","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698\u2013704.","journal-title":"J Clin Oncol"},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","volume":"133","author":"J Godfrey","year":"2019","unstructured":"Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133:2279\u201390.","journal-title":"Blood"},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-019-0233-5","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wenzl K, Manske MK, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019;9:73.","journal-title":"Blood Cancer J"},{"key":"589_CR36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/his.12882","volume":"68","author":"D Kwon","year":"2016","unstructured":"Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology. 2016;68:1079\u201389.","journal-title":"Histopathology"},{"key":"589_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"\u2022 Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481\u20139 In this phase II study, nivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for auto-HCT or who experienced failure with auto-HCT.","journal-title":"J Clin Oncol"},{"key":"589_CR38","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232\u201344.","journal-title":"Clin Cancer Res"},{"key":"589_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869\u201381.","journal-title":"Blood"},{"key":"589_CR40","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DD Twa","year":"2014","unstructured":"Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062\u20135.","journal-title":"Blood"},{"key":"589_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","volume":"130","author":"PL Zinzani","year":"2017","unstructured":"\u2022\u2022 Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267\u201370 In this phase 1b trial, pembrolizumab in heavily pretreated rrPMBCL patients demonstrated a manageable safety profile and promising antitumor activity.","journal-title":"Blood"},{"key":"589_CR42","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","volume":"38","author":"M Shi","year":"2014","unstructured":"Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715\u201323.","journal-title":"Am J Surg Pathol"},{"key":"589_CR43","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"\u2022\u2022 Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071\u20133 This study suggest that nivolumab is active in relapsed\/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.","journal-title":"Blood"},{"key":"589_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","volume":"71","author":"PK Panjwani","year":"2018","unstructured":"Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91\u20139.","journal-title":"Hum Pathol"},{"key":"589_CR45","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/leu.2017.103","volume":"31","author":"V Atsaves","year":"2017","unstructured":"Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633\u20137.","journal-title":"Leukemia"},{"key":"589_CR46","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105:20852\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"589_CR47","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"\u2022\u2022 Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437\u201342 This study demonstrated pembrolizumab as a potent strategy for NK\/T-cell lymphomas failing l-asparaginase regimens.","journal-title":"Blood"},{"key":"589_CR48","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","volume":"100","author":"R Yamamoto","year":"2009","unstructured":"Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A, et al. B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 2009;100:2093\u2013100.","journal-title":"Cancer Sci"},{"key":"589_CR49","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","volume":"19","author":"SK Barta","year":"2019","unstructured":"Barta SK, Zain J, MacFarlane AW, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19:356\u201364 e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"589_CR50","doi-asserted-by":"crossref","unstructured":"\u2022 Shen J, Li S, Medeiros LJ, et al. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2019; This study demonstrated high PD-L1 expression on the anaplastic large cell lymphoma cells, suggesting these patients as potential candidates for PD-1 blockade immunotherapy.","DOI":"10.1038\/s41379-019-0336-3"},{"key":"589_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2019001043","volume":"134","author":"JP Zhang","year":"2019","unstructured":"Zhang JP, Song Z, Wang HB, Lang L, Yang YZ, Xiao W, et al. A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening. Blood. 2019;134:171\u201385.","journal-title":"Blood"},{"key":"589_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","volume":"38","author":"MS Khodadoust","year":"2020","unstructured":"Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38:20\u20138.","journal-title":"J Clin Oncol"},{"key":"589_CR53","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","volume":"95","author":"TS Chan","year":"2016","unstructured":"Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016;95:1913\u20135.","journal-title":"Ann Hematol"},{"key":"589_CR54","doi-asserted-by":"crossref","unstructured":"Rigaud C, Abbou S, Minard-Colin V, Geoerger B, Scoazec JY, Vassal G, et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65.","DOI":"10.1002\/pbc.26902"},{"key":"589_CR55","doi-asserted-by":"publisher","first-page":"607","DOI":"10.7326\/L16-0037","volume":"165","author":"H Hebart","year":"2016","unstructured":"Hebart H, Lang P, Woessmann W. Nivolumab for refractory anaplastic large cell lymphoma: a case report. Ann Intern Med. 2016;165:607\u20138.","journal-title":"Ann Intern Med"},{"key":"589_CR56","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"589_CR57","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18:1611\u20138.","journal-title":"Clin Cancer Res"},{"key":"589_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377\u201381.","journal-title":"Nature"},{"key":"589_CR59","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","volume":"120","author":"KL Tan","year":"2012","unstructured":"Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial. Blood. 2012;120:3280\u20137.","journal-title":"Blood"},{"key":"589_CR60","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362:875\u201385.","journal-title":"N Engl J Med"},{"key":"589_CR61","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130:2420\u201330.","journal-title":"Blood"},{"key":"589_CR62","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1:2643\u201354.","journal-title":"Blood Adv"},{"key":"589_CR63","doi-asserted-by":"publisher","first-page":"e1005642","DOI":"10.1371\/journal.ppat.1005642","volume":"12","author":"SD Ma","year":"2016","unstructured":"Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, et al. PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog. 2016;12:e1005642.","journal-title":"PLoS Pathog"},{"key":"589_CR64","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394.","journal-title":"Blood"},{"key":"589_CR65","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KAL, Green MR, Han E, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015;2:e445\u201355.","journal-title":"Lancet Haematol"},{"key":"589_CR66","doi-asserted-by":"publisher","first-page":"djw257","DOI":"10.1093\/jnci\/djw257","volume":"108","author":"GS Nowakowski","year":"2016","unstructured":"Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, et al. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst. 2016;108:djw257.","journal-title":"J Natl Cancer Inst"},{"key":"589_CR67","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bjh.14432","volume":"180","author":"A Kwiecinska","year":"2018","unstructured":"Kwiecinska A, Tsesmetzis N, Ghaderi M, Kis L, Saft L, Rassidakis GZ. CD274 (PD-L1)\/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma. Br J Haematol. 2018;180:744\u20138.","journal-title":"Br J Haematol"},{"key":"589_CR68","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/path.4522","volume":"236","author":"DD Twa","year":"2015","unstructured":"Twa DD, Mottok A, Chan FC, et al. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol. 2015;236:136\u201341.","journal-title":"J Pathol"},{"key":"589_CR69","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2014.137","volume":"28","author":"D Rossille","year":"2014","unstructured":"Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28:2367\u201375.","journal-title":"Leukemia"},{"key":"589_CR70","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","volume":"4","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4:122\u20136.","journal-title":"Blood Adv"},{"key":"589_CR71","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039\u201341.","journal-title":"Blood"},{"key":"589_CR72","doi-asserted-by":"crossref","unstructured":"Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers. 2018;10.","DOI":"10.3390\/cancers10040099"},{"key":"589_CR73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjh.13167","volume":"168","author":"R Fukano","year":"2015","unstructured":"Fukano R, Mori T, Kobayashi R, Mitsui T, Fujita N, Iwasaki F, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol. 2015;168:557\u201363.","journal-title":"Br J Haematol"},{"key":"589_CR74","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2017.06.026","volume":"83","author":"A Morel","year":"2017","unstructured":"Morel A, Briere J, Lamant L, et al. Long-term outcomes of adults with first-relapsed\/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA\/SFGM-TC study. Eur J Cancer. 2017;83:146\u201353.","journal-title":"Eur J Cancer"},{"key":"589_CR75","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27:516\u201332.","journal-title":"Cancer Cell"},{"key":"589_CR76","first-page":"3692","volume":"9","author":"JD Khoury","year":"2003","unstructured":"Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003;9:3692\u20139.","journal-title":"Clin Cancer Res"},{"key":"589_CR77","doi-asserted-by":"publisher","first-page":"17252","DOI":"10.1038\/s41598-019-53463-0","volume":"9","author":"K Bardhan","year":"2019","unstructured":"Bardhan K, Aksoylar HI, Bourgeois TL, Strauss L, Weaver JD, Delcuze B, et al. Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Sci Rep. 2019;9:17252.","journal-title":"Sci Rep"},{"key":"589_CR78","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149\u201358.","journal-title":"Blood"},{"key":"589_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, \u00d6llinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121\u20135.","journal-title":"Nature"},{"key":"589_CR80","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","volume":"378","author":"L Ratner","year":"2018","unstructured":"Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378:1947\u20138.","journal-title":"N Engl J Med"},{"key":"589_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.humpath.2019.05.007","volume":"90","author":"V Tabanelli","year":"2019","unstructured":"Tabanelli V, Corsini C, Fiori S, Agostinelli C, Calleri A, Orecchioni S, et al. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas. Hum Pathol. 2019;90:60\u20139.","journal-title":"Hum Pathol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-020-00589-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T14:14:06Z","timestamp":1650204846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-020-00589-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00589-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"11 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"WX, LJM, SL, CCY, JDK, and JX declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}